Altor BioScience names new business head
This article was originally published in Scrip
Altor Bioscience, a privately held biotechnology company developing immunotherapies for treating cancer, viral infections, and inflammatory diseases, has named Kevin Taylor chief business officer. He will report to CEO Dr Hing C Wong. Prior to joining Altor, Mr Taylor was chief business officer at Nuron Biotech.
You may also be interested in...
The Scrip 100 universe gathers FY 2019 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales. Here In Vivo breaks out the Top 10 in the league table. Which big pharma holds the top spot this year?
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.